학술논문
Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial
Document Type
Article
Author
Sureda, Anna; González, Ana Pilar; Núñez, Javier; Briones, Javier; De la Cruz, Fátima; Eva, Domingo Domenech; Hernandez, Francisca Maria; Terol, María José; Amutio, Elena; Cordoba, Raul; Martínez, Carmen; Moreno, Miriam; Rodriguez Izquierdo, Antonia; Del Campo, Raquel; Greil, Richard; Romero, Samuel; Garcia-Sanz, Ramón
Source
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p2459-2459, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Introduction. Patients with relapsed/refractory classical Hodgkin's lymphoma (RRHL) still represent a therapeutic challenge. Consolidation with autologous stem cell transplantation (auto-HCT) is the standard of care in this setting. The achievement of a metabolic complete remission (mCR) with salvage chemotherapy (CT) improves long-term outcome after auto-HCT. The introduction of new drugs has significantly changed the landscape of RRHL. Our cooperative group (GELTAMO) has already demonstrated that brentuximab vedotin (BV) + ESHAP (BRESHAP, García-Sanz R et al, Ann Oncol 2019) is able to achieve a mCR rate of 70% before auto-HCT in patients with RRHL. Nevertheless, the superiority of BV + CT vs CT alone has never been tested in prospective randomized clinical trials. Additionally, it is unknown if consolidation treatment with BV could eventually spare auto-HCT in a good risk group of RRHL patients.